Telehealth group counseling for women with heart disease
Utilizing Telehealth Group Counseling Sessions to Improve the Process and Delivery of Secondary Preventive Care for Women With Atherosclerotic Cardiovascular Disease
This study is testing whether telehealth group counseling can help women with heart disease better understand their condition and stick to their treatment plans.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Weill Medical College of Cornell University Academic / other |
| Locations | 1 site (New York, New York) |
| Trial ID | NCT06404515 on ClinicalTrials.gov |
What this trial studies
This study aims to improve engagement and health outcomes for female patients with atherosclerotic cardiovascular disease (ASCVD) through telehealth group counseling sessions. Participants will self-select into an educational series offered via a telehealth platform, where they can choose topics of interest and attend multiple sessions over 12 weeks. The study will collect baseline demographic and health information, as well as pre- and post-session surveys to assess satisfaction and understanding of their conditions. The goal is to enhance adherence to treatment and improve overall health management.
Who should consider this trial
Good fit: Ideal candidates are female patients aged 18 and older with evidence of atherosclerotic cardiovascular disease managed by Weill Cornell Medicine providers.
Not a fit: Patients who have risk factors for heart disease but no evidence of atherosclerotic cardiovascular disease will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to better health outcomes and increased patient engagement for women with heart disease.
How similar studies have performed: Other studies have shown success with telehealth interventions for chronic conditions, indicating potential for this approach in cardiovascular care.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: * Female patients * Age 18 and older * Patients who are managed by providers at the Weill Cornell Medicine Women's Heart Program * Women with evidence of atherosclerotic cardiovascular disease (ASCVD) and diagnoses of chest pain, myocardial infarction/heart attack (myocardial infarction - non ST elevation NSTEMI, ST elevation STEMI), coronary artery disease, acute coronary syndrome, unstable angina, atherosclerotic cardiovascular disease, hypertension (HTN), hyperlipidemia (HLD), diabetes (DM), and/or palpitations (as confirmed by clinician referral to study and chart review) Exclusion criteria: • Women with risk factors (ex: HTN, HLD, DM) but no evidence of ASCVD
Where this trial is running
New York, New York
- Weill Cornell Medicine — New York, New York, United States (Recruiting)
Study contacts
- Principal investigator: Diala Steitieh, MD — Weill Medical College of Cornell University
- Study coordinator: Krista Vadaketh, MD
- Email: kav9064@nyp.org
- Phone: 646-962-5558
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.